Henry Schein stock (US42548G1040): Q1 2026 results and buyback drive sentiment

Henry Schein reports first?quarter 2026 results, reaffirms 2026 guidance, and executes a $125 million share repurchase, supporting investor sentiment.

Henry Schein stock has drawn renewed attention after the company reported first?quarter 2026 financial results and disclosed a $125 million share repurchase, reinforcing its capital?return strategy and growth outlook. The Nasdaq?listed provider of healthcare solutions to office?based dental and medical practitioners reaffirmed its full?year 2026 sales, non?GAAP diluted EPS, and Adjusted EBITDA guidance, signaling confidence in its underlying business despite ongoing macroeconomic pressures. The stock traded at about 77.64 USD per share on Nasdaq during the first quarter, according to Henry Schein investor relations as of May 6, 2026.

As of: 09.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Henry Schein, Inc.
• Sector/industry: Healthcare distribution and services
• Headquarters/country: Melville, New York, United States
• Core markets: North America, Europe, Asia?Pacific, Latin America
• Key revenue drivers: Dental and medical consumables, equipment, technology, and services
• Home exchange/listing venue: Nasdaq (ticker: HSIC)
• Trading currency: USD

Henry Schein: core business model

Henry Schein operates as a global solutions provider for healthcare professionals, supplying products, equipment, and services to office?based dental, medical, and animal health practitioners. The company sources and distributes a broad portfolio of consumables, instruments, and technology platforms, including practice?management software and digital dentistry solutions. Its integrated model combines logistics, financing, and advisory services to help practices manage inventory, workflow, and compliance, which supports recurring revenue streams and long?term customer relationships.

For US investors, Henry Schein is notable as a large?cap healthcare?distribution name with deep exposure to the domestic dental and medical markets. The company’s North American segment represents a significant share of total revenue, and its presence in key growth areas such as digital dentistry and value?oriented implant solutions aligns with structural trends in outpatient care. This positioning makes Henry Schein a relevant barometer for demand in private?practice healthcare settings across the United States.

Main revenue and product drivers for Henry Schein

Henry Schein’s revenue is driven by three broad categories: consumables, equipment and technology, and services. Consumables—such as dental materials, medical supplies, and infection?control products—form the largest share and benefit from steady, recurring demand. Equipment and technology include imaging systems, CAD/CAM units, and dental lasers, which tend to be higher?ticket items but are increasingly influenced by digital?dentistry adoption. Services encompass practice?management software, financing, and consulting, which contribute higher?margin, subscription?like income.

In the first quarter of 2026, Henry Schein highlighted progress in its value?implant strategy, including the acquisition of a controlling interest in its S.I.N. distributor in the United States. This move is designed to strengthen its position in the value implant market and support broader business?integration initiatives. The transaction generated a remeasurement gain of 11 million USD, underscoring the company’s focus on strategic M&A to enhance its product portfolio and market reach. These initiatives are expected to contribute to the targeted 200 million USD of operating?income improvement over the next few years, with a 125 million USD run?rate by year?end 2026.

Capital returns and valuation context

During the first quarter of 2026, Henry Schein repurchased approximately 1.6 million shares of common stock at an average price of 77.64 USD per share, totaling 125 million USD. This buyback reflects management’s view that the stock is attractively valued relative to its earnings power and long?term growth prospects. On a trailing?twelve?month basis, the company reports roughly 12.9 billion USD in revenue and about 391 million USD in net income, implying a market capitalization of around 9 billion USD and a price?to?earnings ratio in the low?20s, according to StockAnalysis.com as of May 6, 2026.

Analyst sentiment remains mixed but generally constructive. A recent note from Mizuho cut the 12?month price target to 82.00 USD, reflecting a more cautious near?term outlook while still acknowledging Henry Schein’s scale and diversified healthcare?distribution franchise. The company’s beta of about 0.82 suggests lower volatility than the broader market, which may appeal to investors seeking relatively defensive exposure within the healthcare sector.

Conclusion

Henry Schein’s first?quarter 2026 results and associated capital?return actions provide a clear near?term narrative for investors: steady underlying demand in dental and medical practices, ongoing margin improvement from value?creation initiatives, and disciplined share repurchases. The company’s diversified product mix and global footprint help insulate it from isolated market shocks, while its focus on digital dentistry and value implants positions it to capture structural growth in outpatient care.

For US investors, Henry Schein offers exposure to a large?cap healthcare?distribution business with recurring revenue characteristics and relatively low beta. However, the stock remains sensitive to macroeconomic conditions, reimbursement trends, and competitive dynamics in equipment and technology. As such, investors may view the current setup as a balance between defensive qualities and growth?oriented initiatives, without any implied recommendation to buy or sell.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.